spacer
home > pmps > summer 2017 > labelling matters
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Labelling Matters

Patients with chronic conditions typically only adhere to 50-60% of medications as prescribed, despite irrefutable evidence that their treatments will increase life quality and expectancy. Non-compliance has been linked to worse health outcomes, more frequent hospitalisations and increased costs. Indeed, a 2003 WHO report stated that more health benefits worldwide would result from improving adherence to existing therapies than from the development of new ones (1). Any intervention that stimulates better compliance to essential medications – even slightly – may therefore play a meaningful role in enhancing public health.

Factors influencing non-adherence are varied, but largely predictable and range from the preventable, such as patients forgetting or misunderstanding, to the non-preventable, such as life-threatening side effects. However, one significant, but often overlooked, enabler of patient attrition is the label.

The importance of labelling gets very little exposure. Nonetheless, product packaging can be a key determinant of patient retention and better health outcomes. The rationale is straightforward: if someone cannot understand the instructions for use, they will be much more inclined to give up. As the cost of drug development escalates and budgetary pressure on the global healthcare economy grows, perhaps it is time for the pharmaceutical industry to review the role of the label in alleviating the expense and implications of patient attrition.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Cusworth is the Vice President of R&D at PRISYM ID. He has over 15 years of experience heading up a team providing off-theshelf and tailored solutions to clinical trial companies. During this time, Mark has seen many changes to the industry, including significant tightening of regulations, challenges of globalisation as well as the shift from subject-based to interactive response technology trials. 
spacer
Mark Cusworth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Porton Biopharma opens new facility to make more of its childhood cancer cure

In a ribbon cutting ceremony, John Glen MP for Salisbury and South Wiltshire today (27th April 2018) officially opened Porton Biopharma Limited’s (PBL) new fermentation facility which will be used to manufacture the company’s life-saving leukaemia drug Erwinase®.   
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

DIA 2018 Global Annual Meeting

24-28 June 2018, Boston, MA

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe. Designed to drive insights into action by connecting key policy discussions to real-world knowledge that you need to do your job every day, your attendance will accelerate your growth and your organization's performance in the development ecosystem.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement